SCS
RPRX icon

Syquant Capital SAS’s Royalty Pharma RPRX Stock Holding History

Syquant Capital SAS’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$250K – 64
2020
Q4 		$250K Buy
+5,000
New +$212K 0.06% 74

Other funds holding RPRX

RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Syquant Capital SAS's RPRX Position: Q1 2021 in Review

Syquant Capital SAS sold out of Royalty Pharma (RPRX) in Q1 2021, closing a stake of 5,000 shares — an estimated $250K sold.

Syquant Capital SAS first reported a position in RPRX in Q4 2020 and held it in 1 quarter. The position peaked at $250K in Q4 2020. 214 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

  • Syquant Capital SAS reported no remaining Royalty Pharma position as of Q1 2021 after selling out during the quarter.
  • Syquant Capital SAS sold 5,000 Royalty Pharma shares in Q1 2021, an estimated $250K.
  • Syquant Capital SAS first reported a position in Royalty Pharma in Q4 2020 and held it in 1 quarter.
  • Syquant Capital SAS's Royalty Pharma position peaked at $250K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on Syquant Capital SAS's 13F filing for Q1 2021, filed 20 Apr 2021.